The groundbreaking rise of Viagra has firmly established as a benchmark of pharmaceutical success, but its position within the broader sector now presents questions about potential gains. Alternative versions are diminishing market share, prompting anxieties that investing in companies significantly dependent to Viagra's former standing could be a